Rheumatic-Heart Disease Management Market Snapshot (2023 to 2033)

The global Rheumatic-Heart Disease Management market size is expected to be valued at USD 1.31 Billion in 2023. With the continuous improvements in drugs and biotechnology, the overall demand for Rheumatic-Heart Disease Management is projected to grow at a CAGR of 4.5% between 2023 and 2033, totaling around USD 2.04 Billion by 2033.

Data Points Key Statistics
Rheumatic-Heart Disease Management Market Value 2023 USD 1.31 Billion
Rheumatic-Heart Disease Management Market Projected Value (2033) USD 2.04 Billion
Rheumatic-Heart Disease Management Market CAGR (2023 to 2033) 4.5%

According to the analysis of Future Market Insights, rheumatic fever is an autoimmune inflammatory disease that can develop as a complication of inadequately treated strep throat. Strep throat is a condition caused by group a of the Streptococcus bacterium. Rheumatic fever is common in the age group of 5 to 15 years, but adults can also have the condition. In certain cases, rheumatic fever can cause long-term damage to the heart and heart valves.

According to the World Health Organization (WHO) report published in April 2018, approximately 30 million people are affected by rheumatic heart disease globally. The increasing occurrences of strep throat and the growing prevalence of rheumatic fever are the major factors that are anticipated to boost the growth of the rheumatic heart disease management market over the analysis period. Additionally, another factor including increasing government expenditure for the healthcare sector is also expected to contribute to the market growth in the near future.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Rheumatic-Heart Disease Management Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for Rheumatic-Heart Disease Management is projected to increase at a CAGR of 4.5% during the forecast period between 2023 and 2033, reaching a total of USD 2.04 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 2.1%.

According to Future Market Insights, a market research and competitive intelligence provider, the Rheumatic-Heart Disease Management market was valued at USD 1.25 Billion in 2022.

In developing economies, rheumatic fever is highly prevalent and remains one of the major causes of rheumatic heart disease. Rheumatic fever is a major cause of mortality among people aged 50 years and above. According to the United Nations Department of Economic and Social Affairs, in 2015, the global population aged 60 years and above was approximately 901 million, and the number is expected to increase significantly over the analysis period.

The population aged 50 years and above has a higher incidence of rheumatic heart disease and mortality rates as compared to younger people. The incidence rate of rheumatic fever is higher in developing countries as compared to developed countries.

According to the Centers for Disease Control and Prevention (CDC), about 23% of adults in the USA, which is over 54 million people, have arthritis. By 2040, the disease is expected to affect 78 million adults in the country. Rheumatic fever is a leading cause of disability. The direct medical costs associated with the disease are over USD 81 Million annually. This disease is more common in women than in men.

Which Drivers underpin Rheumatic-Heart Disease Management Industry Expansion?

Increasing prevalence of Strep Throat and Rheumatic Fever to Fuel the Market Growth

The rising incidences of strep throat are one of the major factors that are projected to augment the growth of the rheumatic heart disease management market during the forecast period. Rheumatic fever is an autoimmune inflammatory disease that can develop as a result of strep throat that hasn't been properly treated. Strep throat is a bacterial infection caused by the Streptococcus bacteria of group A.

It is highly common in low- and middle-income countries, due to a lack of proper sanitation, and healthcare awareness in these countries. According to the statistics by the World Health Organization (WHO), rheumatic heart diseases, such as rheumatic myocarditis is responsible for over 288 348 deaths each year, as of 2020.

Rise in Research & Development Activities to Accelerate the Market Growth

The growth of the rheumatic heart disease management market will also be driven by an increase in the number of research and development activities, which in turn are expected to provide beneficial opportunities for market growth in the coming years. In addition, factors such as a rise in government initiatives, improved healthcare infrastructure, and an increase in the number of emerging markets are expected to create lucrative avenues for market growth during the forecast period.

Additionally, a rise in investment in the healthcare sector in developing countries, and government initiatives to curb the spread of streptococcus bacteria, are expected to accelerate the market growth. For instance, in 2018, the WHO launched a coordinated global response for rheumatic heart disease and rheumatic fever, with the help of WHO’s regional offices. The program includes a road map for the distribution of medicines, vaccines, and other healthcare products by 2023.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which Factors are limiting the Growth of Rheumatic-Heart Disease Management Market?

Lack of Awareness in Low-and-Middle-Income Countries to Restrain the Market Growth

Lack of Awareness regarding the treatment of rheumatic heart disease is one of the major factors that is expected to impede the growth of the Rheumatic-Heart Disease Management Market over the analysis period.

Moreover, the dearth of skilled professionals and lack of healthcare infrastructure in developing economies are other factors that are expected to challenge market growth. In addition, the high cost associated with the treatment of rheumatic heart disease will obstruct the growth rate of the market.

Fewer Treatment Options to Limit the Market Growth

Factors including fewer treatment options available for the treatment of rheumatic heart disease management are likely to hinder the growth of the Rheumatic-Heart Disease Management market in the forthcoming years.

Moreover, rheumatic heart disease can be prevented by effective management of streptococcal sore throat, however, treatment at this early stage is often not achieved. Families may not have the time or money to access a healthcare facility, or may not seek care due to low awareness of the potential risk of untreated ‘strep throat’. Healthcare workers may also not have the necessary knowledge to appropriately diagnose and manage ‘strep throat’. If left untreated, rheumatic fever may then ensue. This in turn is anticipated to hamper the market growth during the forecast period.

Region-wise Insights

Will North America Continue Dominance in the Global Rheumatic-Heart Disease Management Market?

Increase in Prevalence of Rheumatic Fever in the Region to Fuel the Market Growth

The Rheumatic-Heart Disease Management Market in North America is expected to accumulate the highest market share of 45% in 2023.

Factors such as the increasing prevalence of rheumatic fever and the growing focus of major key players on novel technology are expected to boost the regional market growth over the analysis period. Favorable health reimbursement, an increasing number of valve repair and replacement procedures, and a rising obese population are other factors responsible for the market growth in the region.

According to the American Heart Association, 90,000 valve substitutes are implanted in the USA every year. This is poised to surge the demand for prosthetic heart valves in North America, which in turn is anticipated to fuel the market growth. The region is expected to hold the highest CAGR of 4.4% during the forecast period.

How Will the Growth of the Rheumatic-Heart Disease Management Market unfold in Europe?

Rising Prevalence of Rheumatic Heart Disease in the Region to Fuel the Market Growth

The Rheumatic-Heart Disease Management Market in Europe is expected to accumulate the highest market share of 44% in 2023.

In Europe, the market is estimated to expand, attributed to the factors such as the increasing prevalence of rheumatic heart disease and the gradual shift towards minimally invasive procedures. According to the European Society of Cardiology, in 2017, the average proportion of males and females with elevated blood pressure in Europe was 28% and 20% respectively. This is expected to foster the prosthetic Heart Valves Market in Europe.

Moreover, the regional market is projected to grow, owing to the rising geriatric and obese population, rapid adoption of tissue valves, and active government support. The region is expected to hold the highest CAGR of 4.3% during the forecast period.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

By Type, which Rheumatic-Heart Disease Management Category will remain prominent?

Valve Segment to beat Competition in Untiring Market

On the basis of type, the global Rheumatic-Heart Disease Management market is dominated by the Valve Segment, which accounts for a share of 46%. The segment is expected to hold a CAGR of 4.4% over the analysis period.

The high segment’s growth is attributed to factors such as the introduction of new products in the market. Already, the introduction of tissue valves has revolutionized the prosthetic heart valves, which in turn is expected to boost the segment’s growth.

Now, with the launch of products that are minimally invasive and sutureless, the rheumatic heart disease market is expected to gain significant traction. In addition, many manufacturers are carrying out dedicated research and clinical trial for the development of innovative heart valves.

By Application, which Rheumatic-Heart Disease Management Category to dominate?

Hospitals Segment to Drive the Rheumatic-Heart Disease Management Market

Based on the Application, the hospital's segment is expected to witness a significant growth of 46% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 4.3% CAGR over the analysis period.

The segment’s significant growth is attributed to the factors such as the increasing number of procedures in hospitals, favorable health reimbursement, and improving government guidelines for the management of vulvar diseases, which are contributing to the expansion of the market growth.

The Start-up Ecosystem: How key Players are opening Frontiers for Future Growth?

Rheumatic-Heart Disease Management Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,

  • Founded in 2016, Croivalve is a developer of a percutaneous device for treating tricuspid regurgitation. The device seals the gap between the valve leaflets preventing regurgitation. The device is delivered through a vein and into the right heart, restoring the function of the tricuspid valve.
  • Micro Interventional, started in 2010, is developing technologies for percutaneous and minimally invasive structural heart repair procedures. The company has two products - Permaseal, an implant for wound closure for structural heart repair procedures, and Endovalve, a mitral valve replacement system. Products are yet to be approved for commercial use.
  • In 2020, CardioMech, a Transcatheter Mitral Valve Repair Startup announced it had closed on its Series A financing led by a non-disclosed strategic investor together with healthcare specialist investor Hadean Ventures and Investinor. The USD 18.5 million in financing funded its first-in-human feasibility trial.

Who are the Leading Players in the Rheumatic-Heart Disease Management Market?

Prominent players in the Rheumatic-Heart Disease Management market are F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc., Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., Allergan, AstraZeneca, AbbVie Inc., Johnson & Johnson Private Limited, Cipla Inc., Abbott, Merck KGaA, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Limited, Amneal Pharmaceuticals LLC., and Bayer AG, among others.

Recent Developments:

  • In May 2022, Cardiol Therapeutics announced FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of Cardiolrx for recurrent pericarditis.
  • In March 2021, Kiniksa Pharmaceuticals, Ltd. reported the United States Food and Drug Administration (FDA) approved ARCALYST (rilonacept), a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling, for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older.

Report Scope

Report Attribute Details
Growth Rate CAGR of 4.5% from 2023 to 2033
Market Value in 2023 USD 1.31 Billion
Market Value in 2033 USD 2.04 Billion
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered Type, Application, Region
Regions Covered North America; Europe; Europe; Latin America; Middle East & Africa
Key Countries Profiled USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled F. Hoffmann-La Roche Ltd.; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; Sanofi; Pfizer Inc.; GlaxoSmithKline plc.; Novartis AG; Bayer AG; Eli Lilly and Company; Merck & Co., Inc.; Allergan; AstraZeneca; AbbVie Inc.; Johnson & Johnson Private Limited; Cipla Inc.; Abbott; Merck KGaA; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma; Dr. Reddy’s Laboratories Ltd.; Glenmark Pharmaceuticals Limited; Amneal Pharmaceuticals LLC.; Bayer AG

Key Segments Covered in the Rheumatic-Heart Disease Management Industry Analysis

Rheumatic-Heart Disease Management Market by Type:

  • Valve
  • Myocarditis
  • Pericarditis

Rheumatic-Heart Disease Management Market by Application:

  • Hospital
  • Diagnostic Centre
  • Research Centre

Rheumatic-Heart Disease Management Market by Region:

  • North America
  • Europe
  • Europe
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

How Big is the Rheumatic-Heart Disease Management Market?

The market is valued at USD 1.31 billion in 2023.

Who are the Leading Industry Players?

F. Hoffmann-La Roche Ltd., Mylan N.V., and Teva Pharmaceutical Industries Ltd. are the leading industry players.

What is the Growth Forecast for the Rheumatic-Heart Disease Management Industry until 2033?

The industry is set to surge at a CAGR of 4.5% from 2023 to 2033.

What is North America's Expected Market Share until 2023?

North America is likely to generate 45% revenue in 2023.

Which is the Top Trend in the Rheumatic-Heart Disease Management Market?

Rising incidence of strep throat and rheumatic fever driving the expansion of the market

Table of Content
  • 1. Executive Summary
  • 2. Market Overview
  • 3. Market Background
  • 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
  • 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
    • 5.1. Valve
    • 5.2. Myocarditis
    • 5.3. Pericarditis
  • 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
    • 6.1. Hospital
    • 6.2. Diagnostic Centre
    • 6.3. Research Centre
  • 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
    • 7.1. North America
    • 7.2. Latin America
    • 7.3. Europe
    • 7.4. Asia Pacific
    • 7.5. Middle East and Africa (MEA)
  • 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 13. Key Countries Market Analysis
  • 14. Market Structure Analysis
  • 15. Competition Analysis
    • 15.1. Abbott Laboratories
    • 15.2. Bayer
    • 15.3. BIOTRONIK
    • 15.4. Bristol-Myers Squibb
    • 15.5. Cardinal Health
    • 15.6. Cook Medical
    • 15.7. Roche
    • 15.8. GE Healthcare
    • 15.9. Novartis
  • 16. Assumptions & Acronyms Used
  • 17. Research Methodology
Recommendations

Healthcare

Heart Beat Irregularity Detection Device Market

February 2023

REP-GB-14396

234 pages

Healthcare

Heart Closure Devices Market

December 2022

REP-GB-15937

280 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Rheumatic-Heart Disease Management Market

Schedule a Call